MAIA Biotechnology doses first two patients in THIO-101 trial

MAIA Biotechnology announced that the first two patients have been dosed in Europe in MAIA‘s Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer, or NSCLC. Following regulatory clearances in Hungary, Poland, and Bulgaria, five clinical sites have been activated in these three European countries. The primary objectives of the THIO-101 trial are to evaluate the safety and tolerability, as well as preliminary clinical efficacy of THIO, a first-in-class cancer telomere targeting agent, in patients with advanced NSCLC, who either progressed or relapsed through the initial treatments with an immune checkpoint inhibitor alone, or in combination with chemotherapy. The company dosed its first patient in the THIO-101 trial in Australia in July 2022 and commenced dosing patients in Europe in March.